Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Rivaroxaban
Drug ID BADD_D01954
Description Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, 2011.
Indications and Usage Not Available
Marketing Status Prescription
ATC Code B01AF01
DrugBank ID DB06228
KEGG ID D07086
MeSH ID D000069552
PubChem ID 9875401
TTD Drug ID D0KG3R
NDC Product Code 50090-3625; 50458-579; 50458-575; 65015-898; 58032-2029; 55154-1424; 53296-0109; 14799-2023; 55111-966; 76072-1008; 47848-039; 55154-1423; 14501-0079; 65727-050; 52286-0025; 59285-009; 65862-971; 16436-0109; 75945-050; 50090-4468; 53104-7730; 50090-3639; 53747-068; 66022-0203; 50090-4469; 50458-580; 64220-176; 63415-0523; 64552-4049; 50458-578; 46708-899; 82513-0001; 66174-0087; 72969-109; 66039-913; 50458-584; 65372-1193; 50458-577; 55154-1422; 69218-0500
Synonyms Rivaroxaban | 5-chloro-N-(((5S)-2-oxo-3-(4-(3-oxomorpholin-4-yl)phenyl)-1,3-oxazolidin-5-yl)methyl)thiophene-2-carboxamide | Xarelto | BAY 59-7939 | BAY 59 7939 | BAY 597939
Chemical Information
Molecular Formula C19H18ClN3O5S
CAS Registry Number 366789-02-8
SMILES C1COCC(=O)N1C2=CC=C(C=C2)N3CC(OC3=O)CNC(=O)C4=CC=C(S4)Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cerebral amyloid angiopathy24.03.05.010; 17.08.02.017; 10.02.05.0030.000326%Not Available
Cerebellar ischaemia24.04.06.033; 17.08.01.0470.000535%Not Available
Splenic embolism24.01.08.005; 01.09.02.0120.000357%Not Available
Basal ganglia infarction17.08.01.040; 24.04.06.0280.000535%Not Available
Periprosthetic fracture15.08.02.015; 12.02.13.0030.000535%Not Available
Septic encephalopathy17.13.02.011; 11.01.11.0160.000140%Not Available
Brain midline shift17.11.01.0110.003213%Not Available
Coma scale abnormal13.07.03.012--Not Available
Inflammatory marker increased13.09.02.003--Not Available
Intestinal haematoma24.07.02.048; 07.12.03.0070.000186%Not Available
Vascular graft thrombosis24.01.01.036; 12.02.01.0280.001428%Not Available
Helicobacter test positive13.08.01.0100.000714%Not Available
Gastrointestinal vascular malformation24.03.03.031; 07.15.04.0070.001606%Not Available
Pubis fracture12.04.06.004; 15.08.06.0040.000357%Not Available
Distributive shock24.06.02.0220.000535%Not Available
Laryngeal haematoma24.07.01.073; 22.04.01.006; 12.01.09.0150.000357%Not Available
Mesenteric haematoma24.07.02.049; 07.12.03.0080.001071%Not Available
N-terminal prohormone brain natriuretic peptide increased13.02.04.0120.000357%Not Available
Periorbital haemorrhage24.07.05.015; 23.03.11.021; 12.01.04.027; 06.07.02.0080.000535%Not Available
Infectious pleural effusion22.05.01.004; 11.01.09.0110.000535%Not Available
Vertebral artery dissection24.02.04.006; 17.08.06.0040.000357%Not Available
Spinal pain17.10.01.020; 15.02.01.008; 08.01.08.030--Not Available
Protein deficiency14.03.02.0230.000357%Not Available
Meniscus injury15.07.03.006; 12.04.03.008--Not Available
Cerebral ventricle collapse17.07.02.007; 12.02.04.0080.000372%Not Available
Palatal swelling07.05.04.0090.000357%Not Available
Gastrointestinal polyp haemorrhage24.07.02.046; 16.05.03.003; 07.20.01.0110.002142%Not Available
Traumatic haemothorax24.07.01.085; 22.05.02.008; 12.01.03.0100.000714%Not Available
Anticoagulation drug level increased13.17.01.0210.002499%Not Available
Anticoagulation drug level decreased13.17.01.0200.000093%Not Available
The 55th Page    First    Pre   55 56    Next   Last    Total 56 Pages